The stock of Vaxcyte Inc (PCVX) has gone up by 0.62% for the week, with a 16.52% rise in the past month and a -52.05% drop in the past quarter. The volatility ratio for the week is 4.48%, and the volatility levels for the past 30 days are 4.77% for PCVX. The simple moving average for the past 20 days is 2.93% for PCVX’s stock, with a -54.80% simple moving average for the past 200 days.
Is It Worth Investing in Vaxcyte Inc (NASDAQ: PCVX) Right Now?
Moreover, the 36-month beta value for PCVX is 1.21. Analysts have varying opinions on the stock, with 9 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PCVX is 125.07M and currently, short sellers hold a 10.56% of that float. On June 12, 2025, PCVX’s average trading volume was 2.48M shares.
PCVX) stock’s latest price update
The stock of Vaxcyte Inc (NASDAQ: PCVX) has decreased by -1.20 when compared to last closing price of 35.44. Despite this, the company has experienced a 0.62% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-07 that — Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 — — Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Complete Booster Data Up to Nine Months Later —
Analysts’ Opinion of PCVX
Goldman, on the other hand, stated in their research note that they expect to see PCVX reach a price target of $135. The rating they have provided for PCVX stocks is “Buy” according to the report published on December 20th, 2024.
Mizuho gave a rating of “Buy” to PCVX, setting the target price at $69 in the report published on December 07th of the previous year.
PCVX Trading at 7.17% from the 50-Day Moving Average
After a stumble in the market that brought PCVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.08% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCVX starting from Eydelman Mikhail, who sale 5,000 shares at the price of $70.74 back on Mar 05 ’25. After this action, Eydelman Mikhail now owns 41,620 shares of Vaxcyte Inc, valued at $353,699 using the latest closing price.
Eydelman Mikhail, the Officer of Vaxcyte Inc, proposed sale 5,000 shares at $68.87 during a trade that took place back on Mar 05 ’25, which means that Eydelman Mikhail is holding shares at $344,350 based on the most recent closing price.
Stock Fundamentals for PCVX
The total capital return value is set at -0.19. Equity return is now at value -19.66, with -18.64 for asset returns.
Based on Vaxcyte Inc (PCVX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -5.27.
Currently, EBITDA for the company is -448.08 million with net debt to EBITDA at 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.70.
Conclusion
To wrap up, the performance of Vaxcyte Inc (PCVX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
